Physician profile
Pradeep A Chandra
NPI 1124225347
$55,295.02
in general payments reported to CMS, 2019-2025
57 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $1,032 · 2021: $2,880 · 2022: $4,423 · 2023: $2,343 · 2024: $1,209 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,009 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.62 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31,929.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $14,094.96 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $1,694.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $711.33 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $685.19 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $532.81 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $490.93 | 2021-2025 | Verquvo |
| Corcept Therapeutics | $433.26 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.61 | 2019-2025 | Jardiance |
| Amgen INC. | $427.80 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $396.11 | 2019-2024 | |
| Novo Nordisk INC | $339.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Vifor Pharma, INC. | $270.66 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $238.97 | 2019-2025 | Opsumit, Opsynvi, Uptravi |
| Amarin Pharma, INC. | $217.25 | 2019-2021 |
Show all 55 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.